IN THE MANAGEMENT OF TYPE 2 DIABETES^*1

THE POWER TO
ACCOMPLISH
MORE

MULTIPLE BENEFITS.* PROVEN PROTECTION.^†

How soon can we initiate SGLT2i treatment in your HF patients?

06/02/2024 | Author: Boehringer Ingelheim

Document ID: PC-MY-103363

RELATED CONTENT